Mirikizumab – a new option in treatment of inflammatory bowel diseases

Jakub Olszewski; Katarzyna Kozon; Magdalena Sitnik; Katarzyna Herjan; Karolina Mikołap; Bartłomiej Gastoł; Maciej Bara; Piotr Armański; Marcin Sawczuk

doi:10.56782/pps.262

Published : 2024-09-23

Vol. 22 No. 3 (2024)

Mirikizumab – a new option in the treatment of inflammatory bowel diseases

Jakub Olszewski

Katarzyna Kozon

Magdalena Sitnik

Katarzyna Herjan

Karolina Mikołap

Bartłomiej Gastoł

Maciej Bara

Piotr Armański

Marcin Sawczuk

DOI: https://doi.org/10.56782/pps.262

Abstract

ABSTRACT

Mirikizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin IL-23. Over the past few years, it has been the subject of clinical trials as a potential new treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Additionally, mirikizumab has been investigated in clinical trials as a potential treatment for plaque psoriasis. The results of clinical trials for mirikizumab in treating ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for treating adult patients with moderately to severely active ulcerative colitis. Despite promising clinical trial results, mirikizumab has not yet been approved for the treatment of Crohn's disease. This review focuses on summarizing the findings from clinical trials of mirikizumab in the treatment of inflammatory bowel diseases. Information is sourced from scientific papers available on PubMed, by searching for "mirikizumab" and “IL-23” and published to March 2024, as well as from published results of clinical trials concerning mirikizumab.

Keywords:

mirikizumab, IL-23, ulcerative colitis

Most read articles by the same author(s)

Katarzyna Kozon, Małgorzata Krzyżanowska, Jakub Olszewski, Andrzej Patyra, Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
Jakub Olszewski, Katarzyn Kozon, Andrzej Patyra, Flozins in heart failure – a new reimbursement indication , Prospects in Pharmaceutical Sciences: Vol. 20 No. 1 (2022)
Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
Maciej Bara, Agata Janczak, Toxicity of anesthetic gases: exposure in operating rooms and influence on the environment , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patyra, Efficacy of satralizumab therapy in the treatment of NMOSD , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Maciej Bara, Jakub Starownik, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański, Dapagliflozin - new solution in chronic kidney disease treatment , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Katarzyna Herjan, Piotr Armański, Jakub Olszewski, Magdalena Sitnik, Maciej Bara, Positive impact of tranexamic acid in various medical settings , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Olszewski, J., Kozon, K., Sitnik, M., Herjan, K., Mikołap, K., Gastoł, B., … Sawczuk, M. (2024). Mirikizumab – a new option in the treatment of inflammatory bowel diseases. Prospects in Pharmaceutical Sciences, 22(3), 178–185. https://doi.org/10.56782/pps.262

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Tan, Z.Y.; Bealgey, K.W.; Fang, Y.; Gong, Y.M.; Bao, S. Interleukin-23: immunological roles and clinical implications. Int. J. Biochem. Cell Biol. 2009, 41(4), 733-5 DOI: 10.1016/j.biocel.2008.04.027

Duvallet, E.; Semerano, L.; Assier, E.; Falgarone, G.; Boissier, M.C.; Interleukin-23: a key cytokine in inflammatory diseases. Ann. Med. 2011, 43(7), 503- 11, DOI:10.3109/07853890.2011.577093

Tian, Z.; Zhao, Q.; Teng, X. Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease. Front. Immunol. 2024, 15, Art. No: 1393463. DOI: 10.3389/fimmu.2024.1393463

Tang, C.; Chen, S.; Qian, H.; Huang, W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012, 135(2), 112-124. DOI: 10.1111/j.1365-2567.2011.03522.x

Danese, S.; Furfaro, F.; Vetrano, S. Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. J. Crohns Colitis 2017, 12(suppl_2), 678-S86. DOI:10.1093/ecco-jcc/jjx107

Aggarwal, S.; Gurney, A.L. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 2002, 71(1), 1-8. DOI: 10.1189/jlb.71.1.1

Aggarwal, S.; Ghilardi, N.; Xie, M.H.; de Sauvage, F.J.; Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278(3), 1910-1914. DOI:10.1074/jbc.M207577200

Steere, B.; Beidler, C.; Martin, A.; Bright, S.; Kikly, K.; Benschop, R.J. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J. Pharmacol. Exp. Ther. 2023, 387(2), 180-187. DOI:10.1124/jpet.122.001512

Lees, C.W.; Barrett, J.C.; Parkes, M.; Satsangi, J. New IBD genetics: common pathways with other diseases. Gut 2011, 60(12), 739-753 DOI:10.1136/gut.2009.199679

Levin, A.A.; Gottlieb, A.B. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J. Am. Acad. Dermatol. 2014, 70(3), 555-561. DOI: 10.1016/j.jaad.2013.10.043

Elson, C.O.; Cong, Y.; Weaver, C.T.; Schoeb, T.R.; McClanahan, T.K.; Fick, R.B. et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007, 132(7), 2359-70. DOI:10.1053/j.gastro.2007.03.104

Hammerhøj, A.; Boye, T.L.; Langholz, E.; Nielsen, O.H. Mirikizumab (Omvoh™) for ulcerative colitis. Trends Pharmacol. Sci. 2024, 45(3), 281-2. DOI:10.1016/j.tips.2024.01.001

Feuerstein, J.D.; Cheifetz, A.S. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin. Proc. 2014, 89(11), 1553-1563. DOI:10.1016/j.mayocp.2014.07.002

Tontini, G.E.; Vecchi, M.; Pastorelli, L.; Neurath, M.F.; Neumann, H. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J. Gastroenterol. 2015, 21(1), 21-46. DOI:10.3748/wjg.v21.i1.21

Rao, S.S.; Holdsworth, C.D.; Read, N.W. Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988, 29(3), 342-5. DOI:10.1136/gut.29.3.342

Raine, T.; Bonovas, S.; Burisch, J.; Kucharzik, T.; Adamina, M.; Annese, V. et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J. Crohns Colitis 2021, 16(1), 2-17. DOI:10.1093/ecco-jcc/jjab178

Danese, S.; Fiocchi, C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 2006, 12(30), 4807-12. DOI:10.3748/wjg.v12.i30.4807

Dragasevic, S.; Stankovic, B.; Sokic-Milutinovic, A.; Milosavljevic, T.; Milovanovic, T.; Lukic, S. et al. Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: Gene expression profiling study. Clin. Immunol. 2018, 197, 86-95. DOI:10.1016/j.clim.2018.09.001

Sandborn, W.J.; Ferrante, M.; Bhandari, B.R.; Berliba, E.; Feagan, B.G.; Hibi, T. et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology 2020, 158(3), 537-549.e10. DOI: 10.1053/j.gastro.2019.08.043

Sandborn, W.J.; Sands, B.E.; Vermeire, S.; Leung, Y.; Guo, X.; Modesto, I. et al. Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Therap. Adv. Gastroenterol. 2022, 15, Art. No: 7562848221136331. DOI: 10.1177/17562848221136331

II phase clinical trial of mirikizumab in UC [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT02589665.

Sandborn, W.J.; Ferrante, M.; Bhandari, B.R.; Berliba, E.; Hibi, T.; D'Haens, G.R. et al. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin. Gastroenterol. Hepatol. 2022, 20(1), 105-115.e14. DOI: 10.1016/j.cgh.2020.09.028

Badanie LUCENT-1 - III faza badań klinicznych mirikizumabu w leczeniu UC [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03518086.

Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study. Gastroenterol. Hepatol. 2022; 18(4 Suppl 1), 7-8.

D’Haens, G.; Kobayashi, T.; Morris, N.; Lissoos, T.; Hoover, A.; Li, X. et al. OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study. J. Crohns Colitis 2022, 16(Supplement_1), i028-i029. DOI: 10.1093/ecco-jcc/jjab232.025

D’Haens, G.; Dubinsky, M.; Kobayashi, T.; Irving, P.M.; Howaldt, S.; Pokrotnieks, J. et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2023, 388(26), 2444-2455. DOI:10.1056/NEJMoa2207940

LUCENT-2 Badanie podtrzymujące z zastosowaniem mirikizumabu u uczestników z umiarkowanie do ciężko aktywną postacią wrzodziejącego zapalenia jelita grubego. [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03524092

Kobayashi, T.; Matsuoka, K.; Watanabe, M.; Hisamatsu, T.; Hirai, F.; Milata, J. et al. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies. Intest. Res. 2024, 22(2), 172-85. DOI:10.5217/ir.2023.00043

LUCENT -3. Badanie oceniające długoterminową skuteczność i bezpieczeństwo mirikizumabu u uczestników z umiarkowanie do ciężko aktywną postacią wrzodziejącego zapalenia jelita grubego. [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03519945.

Sands, B.E.; D’Haens, G.; Clemow, D.B.; Irving, P.M.; Johns, J.T.; Hunter, T. et al. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm. Bowel Dis. 2024, 30(6), 1044-1045. DOI: 10.1093/ibd/izae024

SHINE1 - Badanie mirikizumabu u dzieci i nastolatków z wrzodziejącym zapaleniem jelita grubego [accesed and cited 2024 27.07] Available from: https://clinicaltrials.gov/study/NCT04004611.

PK, Efficacy, and Safety of Mirikizumab as Induction Therapy in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 2 SHINE-1 Study. Gastroenterol. Hepatol. 2023, 19(7 Suppl 3), 8-9.

Informacja producenta dotycząca dopuszczenia mirikizumabu (Omvoh) na terenie USA we wskazaniu do leczenia umiarkowanej i ciężkiej postaci UC u osób dorosłych [accesed and cited 2024 27.07]. Available from: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class

Informacja ze strony Europejskiej Agencji Leków (EMA) dotycząca leku Omvoh (mirikizumab) [accesed and cited 2024 27.07]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/omvoh

Decyzja o dopuszczeniu leku Omvoh(mirikizumab) na terenie Kanady do leczenia umiarkowanego i ciężkiego UC [accesed and cited 2024 27.07]. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1695821197450.

Decyzja Japońskiej Agencji Leków o dopuszczeniu leku Omvoh (mirikizumab) do obrotu na terenie Japonii do leczenia umiarkowanej i ciężkiej postaci UC u dorosłych [accesed and cited 2024 27.07]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/23994A5.

Shanahan, F. Crohn's disease. The Lancet. 2002, 359(9300), 62-9. DOI: 10.1016/S0140-6736(02)07284-7

Baumgart, D.C.; Sandborn, W.J. Crohn's disease. The Lancet. 2012, 380(9853), 1590-605.DOI:10.1016/S0140-6736(12)60026-9

SERENITY - badanie skuteczności mirikizumabu u pacjentów z aktywną chorobą Crohna [accesed and cited 2024.27.07]. Available from: https://clinicaltrials.gov/study/NCT02891226.

Avedillo-Salas, A.; Corral-Cativiela, S.; Fanlo-Villacampa, A.; Vicente-Romero, J.; The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate-Severe Crohn's Disease: A Systematic Review. Pharmaceuticals (Basel) 2023, 16(11), ARt. No: 1581. DOI: 10.3390/ph16111581

Sands, B.E.; Peyrin-Biroulet, L.; Kierkus, J.; Higgins, P.D.R.; Fischer, M.; Jairath, V. et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology 2022, 162(2), 495-508. DOI:10.1053/j.gastro.2021.10.050

VIVID-1 - badanie skutecznośći mirikizumabu w leczeniu dorosłych pacjentów z umiarkowaną do ciężkiej postacią choroby Crohna [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03926130.

Aslam, M.; Ali, M.H.; Irfan, H.; Mirikizumab: A promising breakthrough in Crohn's disease treatment. Health Sci. Rep. 2024, 7(8), Art. No: e2294. DOI:10.1002/hsr2.2294

Ferrante, M.; Danese, S.; Chen, M.; D'Haens, G.; Ghosh, S.; Hisamatsu, T. et al. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study. J. Crohns Colitis 2024, 18(Supplement_1), i7-i9. DOI: 10.1093/ecco-jcc/jjad212.0005

Jairath, V.; Sands, B.E.; Bossuyt, P.; Farraye, F.; Ferrante, M.; Hisamatsu, T. et al. OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study. J. Crohns Colitis 2024, 18(Supplement_1), i62-i4. DOI:10.1093/ecco-jcc/jjad212.0035

VIVID-2 - Długoterminowe badanie rozszerzone mirikizumabu u uczestników z chorobą Leśniowskiego-Crohna [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT04232553.

Jakub Olszewski

olszewskij3@gmail.com

Katarzyna Kozon

Affiliation:

Prof. W. Orłowski Memorial Hospital, 00-401 Warsaw, Poland Poland

Magdalena Sitnik

Affiliation:

Masovian Brodnowski Hospital, 03-242 Warsaw, Poland Poland

Katarzyna Herjan

Affiliation:

Prof. W. Orłowski Memorial Hospital, 00-401 Warsaw, Poland Poland

Karolina Mikołap

Affiliation:

Wolski Hospital in Warsaw, 01-211 Warsaw, Poland Poland

Bartłomiej Gastoł

Affiliation:

Masovian Specialist Hospital in Ostrołęka, 07-410 Ostrołęka, Poland Poland

Maciej Bara

Affiliation:

Infant Jesus Clinical Hospital, Medical University of Warsaw, 02-005 Warsaw, Poland Poland

Piotr Armański

Affiliation:

District Hospital in Sochaczew, 96-500 Sochaczew, Poland Poland

Marcin Sawczuk

Affiliation:

Medical University of Gdansk Clinical Center, 80-952 Gdańsk, Poland Poland